

Special Issue

Bacterial Carbohydrate and Protein Vaccine Research

Message from the Guest Editors

Vaccines are one of the most cost-effective way to control infectious diseases. Protein vaccines are composed of purified or recombinant proteinaceous antigens from a pathogen, such as a bacterium or virus. In addition to protein antigens, cell surface carbohydrates are widely used as antigenic components of vaccines. Glycoconjugate vaccines are composed of carbohydrate antigens, covalently linked to a carrier moiety, usually a non-toxic protein. This Special Issue focuses on protein vaccine and bacterial carbohydrate vaccine. Submission of original articles, systematic reviews, short communications, and other types of article on related topics are welcome. Manuscripts will follow standard Journal peer-review practices, and those accepted for publication will appear in the special issue on Bacterial Carbohydrate and Protein Vaccine Research. We look forward to receiving and welcome your contributions. Keywords:

- Protein Vaccine
- Polysaccharide Vaccine
- Bacterial Carbohydrates
- Glycoconjugates
- Immunogens
- Peptide Antigens
- Vaccine Adjuvants

Guest Editors

Dr. Vana Spoulou

School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Prof. John Routsias

Department of Microbiology, Athens Medical School, 11527 Athens, Greece

Deadline for manuscript submissions

closed (30 April 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/64919

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).